<DOC>
	<DOCNO>NCT03085823</DOCNO>
	<brief_summary>The purpose study observe evaluate performance Sirolimus-eluting Drug Coated Balloon treatment type coronary lesion , include native vessel disease stent restenosis .</brief_summary>
	<brief_title>The All-comers Sirolimus-coated Balloon European Registry</brief_title>
	<detailed_description />
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>age least 18 patient symptomatic coronary artery disease ( include chronic stable angina , silent ischemia , acute coronary syndrome ) clinical indication percutaneous coronary intervention . patient one follow criterion : know ( untreatable ) hypersensitivity contraindication Aspirin , Heparin , Clopidogrel , Prasugrel , Ticagrelor , Sirolimus , sensitivity contrast medium adequately premedicated . patient enrol another trial . Target lesion/vessel follow characteristic : successful predilatation perform target lesion , efficacious ( residual stenosis &gt; 50 % ) ; severe calcification target vessel , also proximal lesion ; highly tortuous lesion impair access device treatment site . visible thrombus lesion treatable aspiration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>